This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 9.72% and 11.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 4.35% and 2.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Stoke Therapeutics (STOK) This Earnings Season?
by Zacks Equity Research
Stoke Therapeutics (STOK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Stoke Therapeutics, Inc. (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Stoke Therapeutics, Inc. (STOK), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
How Much Upside is Left in Stoke Therapeutics, Inc. (STOK)? Wall Street Analysts Think 91%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 90.7% in Stoke Therapeutics, Inc. (STOK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 10% and 19.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Acadia (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Acadia (ACAD) posts wider-than-expected loss for the first quarter of 2022 while revenues miss estimates.
Humana (HUM) Gears Up For Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Humana's (HUM) first-quarter earnings are likely to reflect the impacts of elevated costs related to investments in technology advancements, partly offset by higher premiums in the Retail segment and sound membership growth.
Acadia (ACAD) Q4 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Acadia (ACAD) posts a wider-than-expected loss for the fourth quarter of 2021. Shares fall during the after-hours trading.
Wall Street Analysts Believe Stoke Therapeutics, Inc. (STOK) Could Rally 184%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 184.3% in Stoke Therapeutics, Inc. (STOK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 192% Upside in Stoke Therapeutics, Inc. (STOK): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 192.2% upside potential for Stoke Therapeutics, Inc. (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q3
by Zacks Equity Research
Immunovant's (IMVT) earnings miss estimates in fiscal third-quarter, which ended on Dec 31, 2021. Focus remains on lead pipeline candidate batoclimab.
Acadia (ACAD) Up More Than 20% in Past 3 Months: Here's Why
by Zacks Equity Research
Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, has seen strong uptake so far. Its label expansion studies also hold promise.
Acadia (ACAD) Partners With Stoke for CNS Disorder Therapies
by Zacks Equity Research
Acadia (ACAD) signs a collaboration agreement with Stoke Therapeutics to develop/commercialize RNA-based medicines for addressing genetic neurodevelopmental diseases.
Ultragenyx's (RARE) IND for mRNA Therapy, UX053 Cleared by FDA
by Zacks Equity Research
The FDA clears Ultragenyx's (RARE) investigational new drug application for UX053 being developed to treat Glycogen Storage Disease Type III.
ACADIA (ACAD) Falls as FDA Finds Deficiencies in Nuplazid sNDA
by Zacks Equity Research
The FDA identifies deficiencies in ACADIA's (ACAD) sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with dementia-related psychosis. Stock sinks.
Cara Therapeutics' (CARA) Korsuva NDA Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts Cara Therapeutics (CARA) and Vifor Pharma's NDA for Korsuva injection under a priority review to treat moderate-to-severe pruritus in hemodialysis patients. Shares rise.
Stoke Therapeutics, Inc. (STOK) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Stoke Therapeutics, Inc. (STOK).
Can The Uptrend Continue for Stoke Therapeutics?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Stoke Therapeutics.
Will Stoke Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Stoke Therapeutics.